ProShare Advisors’s Mustang Bio MBIO Stock Holding History

ProShare Advisors’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31	Closed	-$23K	–	1982
2022 Q1	$23K	Sell	31 -8	-21%	-$6.57K	﹤0.01%	2170
2021 Q4	$48K	Buy	+39	New	+$63K	﹤0.01%	2290
2021 Q3	–	Sell	-24	Closed	-$60K	–	2150
2021 Q2	$60K	Buy	24 +6	+33%	+$14.7K	﹤0.01%	2347
2021 Q1	$45K	Buy	18 +3	+20%	+$8.92K	﹤0.01%	2230
2020 Q4	$42K	Buy	+15	New	+$35.9K	﹤0.01%	2060

Other funds holding MBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

ProShare Advisors's MBIO Position: Q2 2022 in Review

ProShare Advisors sold out of Mustang Bio (MBIO) in Q2 2022, closing a stake of 31 shares — an estimated $23K sold.

ProShare Advisors first reported a position in MBIO in Q4 2020 and held it in 5 quarters. The position peaked at $60K in Q2 2021. 71 funds tracked by Wall St. Rank hold MBIO as of Q2 2022.

ProShare Advisors reported no remaining Mustang Bio position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 31 Mustang Bio shares in Q2 2022, an estimated $23K.
ProShare Advisors first reported a position in Mustang Bio in Q4 2020 and held it in 5 quarters.
ProShare Advisors's Mustang Bio position peaked at $60K in Q2 2021.
71 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.